{"organizations": [], "uuid": "c56e1698add5b0da181af42f6c90ee69fc8606ba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abeona-announces-fda-grants-rmat-d/brief-abeona-announces-fda-grants-rmat-designationto-abo-102-gene-therapy-in-mps-iiia-idUSFWN1S00OI", "country": "US", "domain_rank": 408, "title": "BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T15:17:00.000+03:00", "replies_count": 0, "uuid": "c56e1698add5b0da181af42f6c90ee69fc8606ba"}, "author": "", "url": "https://www.reuters.com/article/brief-abeona-announces-fda-grants-rmat-d/brief-abeona-announces-fda-grants-rmat-designationto-abo-102-gene-therapy-in-mps-iiia-idUSFWN1S00OI", "ord_in_thread": 0, "title": "BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia", "locations": [], "entities": {"persons": [], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "abeona therapeutics inc", "sentiment": "none"}, {"name": "mps iiia reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 17 PM / Updated 6 minutes ago BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia Reuters Staff \nApril 23 (Reuters) - Abeona Therapeutics Inc: \n* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA \n* ABEONA THERAPEUTICS INC - COMPANY CONTINUES TO ENGAGE FDA ON ITS ONGOING PHASE 1/2 TRIAL \n* ABEONA - FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION TO ABO-102, COâ€™S GENE THERAPY FOR TREATMENT OF SANFILIPPO SYNDROME TYPE A Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-23T15:17:00.000+03:00", "crawled": "2018-04-23T15:26:16.004+03:00", "highlightTitle": ""}